<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808531</url>
  </required_header>
  <id_info>
    <org_study_id>MDC-NB-P3-01</org_study_id>
    <nct_id>NCT04808531</nct_id>
  </id_info>
  <brief_title>NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) &amp; Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers</brief_title>
  <official_title>NanaBis™ an Oro-buccal Administered Equimolar d9-THC &amp; CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active &amp; Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medlab Clinical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>WriteSource Medical Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medlab Clinical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a&#xD;
      monotherapy treatment in participants 18-70 years of age with cancer related pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial uses an alternative method to demonstrate the analgesic efficacy of NanaBis™ as a&#xD;
      monotherapy in cancer participants. Proving analgesic efficacy requires demonstrating that&#xD;
      (i) the analgesic is significantly better than placebo and (ii) that the magnitude of the&#xD;
      improvement is clinically important. The latter is standardly done by measuring the change in&#xD;
      pain levels from a baseline (no analgesia) to the end of a treatment period. A 30% decrease&#xD;
      in the Numerical Pain Rating Scale (NPRS) has been correlated with participants reporting a&#xD;
      moderate improvement in their pain and this was adopted as the standard method of&#xD;
      demonstrating a clinically important magnitude of improvement. In this strategy, the measure&#xD;
      of analgesic efficacy is the proportion of participants in the treatment group whose pain is&#xD;
      adequately treated (responders). A responder is defined as a patient who completes the&#xD;
      treatment phase with an acceptable level of pain (NPRS ≤ 5) and without requiring excessive&#xD;
      amounts of rescue (breakthrough analgesia) medication. Unlimited breakthrough analgesia&#xD;
      (oxycodone) is allowed throughout the study; however, excessive use will result in&#xD;
      discontinuation. Comparison of the proportion of responders in the NanaBis™ arm and placebo&#xD;
      arms will determine if NanaBis™ is significantly better than placebo. Demonstrating that the&#xD;
      proportion of responders in the NanaBis™ arm is non-inferior to the Oxycodone controlled&#xD;
      release (CR) comparator arm will determine if the magnitude of improvement (provided by&#xD;
      NanaBis™) is clinically important because Oxycodone CR has been established as the benchmark&#xD;
      analgesic that provides a clinically important effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Significant changes in responders with NanaBis™ spray over placebo (p&lt;0.05)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To demonstrate that at the end of the 6-week study period the proportion of responders in the NanaBis™ group shows significant change than the proportion of responders in the placebo group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparable efficacy in proportion of responders from NanaBis™ spray to the proportion of responders to Oxycodone CR</measure>
    <time_frame>6 weeks</time_frame>
    <description>To demonstrate that at the end of the 6-week study period the proportion of responders in the NanaBis™ group is similar to the proportion of responders in the Oxycodone group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant change in the Health-Related Quality of Life Scores Form (36) Health Survey (SF-36) with NanaBis™ spray over placebo (p&lt;0.05) and comparable to Oxycodone CR</measure>
    <time_frame>6 weeks</time_frame>
    <description>To demonstrate that at the end of the 6-week study period the Health-Related Quality of Life scores in the Scores Form (36) Health Survey (SF-36) for the NanaBis™ group are significantly changed than in the Placebo group and is similar to the Oxycodone group.&#xD;
Change in the Health Survey Scores Form (SF-36) at End of Titration and Optimal Dose Period [Time Frame: Baseline; End of Week 3 (3 weeks)]; and at End of Treatment Period [Time Frame: Baseline; End of Week 6 (3 weeks)]; and at End of Compassionate Period [Time Frame: Baseline; End of Week 18 (12 weeks)]&#xD;
The Scores Form 36 (SF-36) includes 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant scores. Higher scores indicate improvement in health. Domain scale scores 0 (negative health) to 100 (positive health). 100 represents the best health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change in the painDETECT score with NanaBis™ spray over placebo (p&lt;0.05) and comparable to Oxycodone CR</measure>
    <time_frame>18 weeks</time_frame>
    <description>painDETECT Assessment at Baseline [Time Frame: Baseline]. painDETECT questionnaire was used to determine the possibility of the presence of a neuropathic pain component.&#xD;
painDETECT Assessment for Participants at End of Titration and Optimal Dose Period [Time Frame: End of Week 1 to 3]; painDETECT Assessment for Participants at End of the Treatment Period [Time Frame: End of Weeks 4 to 6]; painDETECT Assessment for Participants at End of the Compassionate Period [Time Frame: End of Weeks 7 to 18].&#xD;
painDETECT is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being &quot;negative&quot; (no neuropathic pain component). Value between 19 and 38 as being &quot;positive&quot; (presence of neuropathic component)&quot;. Values from 13 to 18 are scored as being &quot;unclear&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NanaBis™ Adverse Events</measure>
    <time_frame>18 weeks</time_frame>
    <description>To demonstrate that at the end of the 6-week study period that NanaBis™ is safe and tolerable. The daily use of NanaBis™ oro-buccal spray reduces the severity of Treatment-Emergent Adverse Events (safety and tolerability). [Time Frame: Change from Baseline and Titration and Treatment in UKU-Side Effects Rating Scale for Patients (UKU-SERS-Pat) at Weeks 1 to 3 and 4 to 6.]&#xD;
Does the daily use of NanaBis™ oro-buccal spray reduce the severity of Treatment-Emergent Adverse Events (safety and tolerability). [Time Frame: Change during Compassionate Use in UKU-SERS-Pat at Weeks 7 to 18.]&#xD;
Changes in validated UKU-SERS-Pat scale range is 0 to 3 for rating the degree of severity (mild, moderate or severe) and a second scale for the investigator that assigns a casual relationship of improbable, possible or probable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fifty percent or greater request compassionate extension with NanaBis™ spray</measure>
    <time_frame>12 weeks</time_frame>
    <description>To demonstrate that at the end of the 6-week study period that after unblinding, half or more of the NanaBis™ group prefer further treatment with NanaBis™ in the compassionate extension phase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Cancer Related Pain</condition>
  <arm_group>
    <arm_group_label>Double Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Spray Placebo + Tablet Placebo Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian Office of Drug Control (ODC) (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.&#xD;
Tablet Placebo will be identical to the Oxycontin tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment NanaBis™ Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NanaBis™ + Tablet Placebo NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC and CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD. The dose administered will be 2 - 3 doses per 4 hours unless asleep.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator (Oxycodone) Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spray Placebo + Oxycodone CR Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian ODC (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.&#xD;
Oxycodone controlled release (CR) used as a comparator will be Oxycontin tablets 10 mg - 70 mg po bd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NanaBis™</intervention_name>
    <description>NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC &amp; CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD</description>
    <arm_group_label>Treatment NanaBis™ Arm</arm_group_label>
    <other_name>MDCNB-01</other_name>
    <other_name>NanoCelle® d9-THC &amp; CBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone CR</intervention_name>
    <description>Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.</description>
    <arm_group_label>Comparator (Oxycodone) Arm</arm_group_label>
    <other_name>OxyNorm®</other_name>
    <other_name>OxyContin®</other_name>
    <other_name>Endone®</other_name>
    <other_name>Proladone®</other_name>
    <other_name>Targin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Spray</intervention_name>
    <description>Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.</description>
    <arm_group_label>Comparator (Oxycodone) Arm</arm_group_label>
    <arm_group_label>Double Placebo Arm</arm_group_label>
    <other_name>NanoCelle® Placebo Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.</description>
    <arm_group_label>Double Placebo Arm</arm_group_label>
    <arm_group_label>Treatment NanaBis™ Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        At Screening Phase&#xD;
&#xD;
        Participants must fulfil all of the following criteria:&#xD;
&#xD;
          -  Prospective male and female participants in the age range 18-70 years&#xD;
&#xD;
          -  Metastatic bone pain from a cancer diagnosis is the only major cause of pain. Markers&#xD;
             of disease progression (e.g. tenderness or unrelieved pain with changes in posture)&#xD;
             may need to be randomised&#xD;
&#xD;
          -  Pathology (blood, imaging) confirmed metastatic bone cancer&#xD;
&#xD;
          -  Meet International Classification of Diseases-10 (ICD-10) codes for pain management&#xD;
             criteria (i.e., bone cancer pain)&#xD;
&#xD;
          -  During the screening period, the participant is on stable opioid pain management and&#xD;
             pain severity (NPRS) ≤ 8 with a maximum variation of ± 1&#xD;
&#xD;
          -  Pain Detect score &gt; 18&#xD;
&#xD;
          -  Participant willing and able to provide informed consent and follow study procedures&#xD;
&#xD;
               1. including agreeing to not drive or operate heavy machinery; and&#xD;
&#xD;
               2. females of child-bearing potential agree to use reliable contraception during the&#xD;
                  duration of the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At Screening Phase&#xD;
&#xD;
        Participants will be excluded if they meet any of the following criteria that include:&#xD;
&#xD;
          -  History of epilepsy or recurrent seizures&#xD;
&#xD;
          -  Moderate to severe medical conditions such as&#xD;
&#xD;
               1. severe hepatic;&#xD;
&#xD;
               2. cardiovascular or renal impairment; or&#xD;
&#xD;
               3. psychiatric disorders (i.e., unstable schizophrenia, recent drug-induced&#xD;
                  psychosis, severe mood disorders), that would be assessed at the medical screen&#xD;
&#xD;
          -  Presence of substance abuse disorder such as nicotine or alcohol, or other illicit or&#xD;
             prescription drug dependence (e.g., opioid dependence), or methadone or buprenorphine&#xD;
             treatment for opioid dependence&#xD;
&#xD;
          -  Women who are pregnant, lactating or planning to become pregnant&#xD;
&#xD;
          -  Identified concerns by the nursing / medical team relevant to the safe storage of&#xD;
             medications (i.e., NanaBis™ or standard medical therapy)&#xD;
&#xD;
          -  Participant may not be available for follow up (i.e., planned or expected travel or&#xD;
             other)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. Luis Vitetta</last_name>
    <phone>+61 8188 0311</phone>
    <phone_ext>106</phone_ext>
    <email>luis_vitetta@medlab.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Michael Lyon</last_name>
    <phone>+1 604 777 5500</phone>
    <email>doctorlyon@me.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.tga.gov.au/sites/default/files/ich13595an.pdf</url>
    <description>Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) - annotated with TGA comments. DSEB. 2000.</description>
  </link>
  <link>
    <url>https://www.tga.gov.au/sites/default/files/ich37795.pdf</url>
    <description>Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95). Annotated with TGA comments,. 2001.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/books/NBK476449/</url>
    <description>VA Evidence-based Synthesis Program Reports. In Benefits and Harms of Cannabis in Chronic Pain or Post-traumatic Stress Disorder: A Systematic Review, Department of Veterans Affairs (US): Washington (DC), 2017.</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/10.1111/ajco.13498</url>
    <description>Pilot clinical and pharmacokinetic study of a water soluble nanoparticle cannabis-based medicine in advanced cancer with intractable pain. S. Clarke, B. Butcher, A.J McLachlan, J.D Henson, D. Rutolo, S. Hall, L. Vitetta. 2020. Abstract 219</description>
  </link>
  <reference>
    <citation>Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9.</citation>
    <PMID>11690728</PMID>
  </reference>
  <reference>
    <citation>Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014 Jul-Aug;17(4):329-43.</citation>
    <PMID>25054392</PMID>
  </reference>
  <reference>
    <citation>Anderson W. 2007 National Statement on Ethical Conduct in Human Research. Intern Med J. 2011 Jul;41(7):581-2. doi: 10.1111/j.1445-5994.2011.02528.x.</citation>
    <PMID>21762341</PMID>
  </reference>
  <reference>
    <citation>Portenoy RK. Treatment of cancer pain. Lancet. 2011 Jun 25;377(9784):2236-47. doi: 10.1016/S0140-6736(11)60236-5. Review.</citation>
    <PMID>21704873</PMID>
  </reference>
  <reference>
    <citation>Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008 Dec;19(12):1985-91. doi: 10.1093/annonc/mdn419. Epub 2008 Jul 15. Review.</citation>
    <PMID>18632721</PMID>
  </reference>
  <reference>
    <citation>Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003868. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD003868.</citation>
    <PMID>17943804</PMID>
  </reference>
  <reference>
    <citation>Kane CM, Hoskin P, Bennett MI. Cancer induced bone pain. BMJ. 2015 Jan 29;350:h315. doi: 10.1136/bmj.h315. Review.</citation>
    <PMID>25633978</PMID>
  </reference>
  <reference>
    <citation>Gregorian RS Jr, Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010 Nov;11(11):1095-108. doi: 10.1016/j.jpain.2010.02.007. Epub 2010 May 10.</citation>
    <PMID>20452835</PMID>
  </reference>
  <reference>
    <citation>Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone Metastases: An Overview. Oncol Rev. 2017 May 9;11(1):321. doi: 10.4081/oncol.2017.321. eCollection 2017 Mar 3. Review.</citation>
    <PMID>28584570</PMID>
  </reference>
  <reference>
    <citation>Choong PF. The molecular basis of skeletal metastases. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S19-31. Review.</citation>
    <PMID>14600589</PMID>
  </reference>
  <reference>
    <citation>Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, de Bono J, Attard G. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):270-273. doi: 10.1016/j.eururo.2013.10.055. Epub 2013 Nov 22.</citation>
    <PMID>24295792</PMID>
  </reference>
  <reference>
    <citation>Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000 May;31(5):578-83.</citation>
    <PMID>10836297</PMID>
  </reference>
  <reference>
    <citation>Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S. Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid. J Bone Oncol. 2017 Aug 31;8:18-22. doi: 10.1016/j.jbo.2017.08.004. eCollection 2017 Sep.</citation>
    <PMID>28884071</PMID>
  </reference>
  <reference>
    <citation>Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J. Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol. 2017 Jul;115:67-80. doi: 10.1016/j.critrevonc.2017.04.008. Epub 2017 Apr 23. Review.</citation>
    <PMID>28602171</PMID>
  </reference>
  <reference>
    <citation>Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s. Review.</citation>
    <PMID>17062708</PMID>
  </reference>
  <reference>
    <citation>Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis Primers. 2017 Feb 16;3:17002. doi: 10.1038/nrdp.2017.2. Review.</citation>
    <PMID>28205574</PMID>
  </reference>
  <reference>
    <citation>Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr. 2018 Jun;41(3):60-63. doi: 10.18773/austprescr.2018.022. Epub 2018 Jun 1. Review.</citation>
    <PMID>29921999</PMID>
  </reference>
  <reference>
    <citation>Mantyh PW. Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care. 2014 Jun;8(2):83-90. doi: 10.1097/SPC.0000000000000048. Review.</citation>
    <PMID>24792411</PMID>
  </reference>
  <reference>
    <citation>Ahmad I, Ahmed MM, Ahsraf MF, Naeem A, Tasleem A, Ahmed M, Farooqi MS. Pain Management in Metastatic Bone Disease: A Literature Review. Cureus. 2018 Sep 11;10(9):e3286. doi: 10.7759/cureus.3286. Review.</citation>
    <PMID>30443456</PMID>
  </reference>
  <reference>
    <citation>Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesth Analg. 2017 Nov;125(5):1638-1652. doi: 10.1213/ANE.0000000000002110. Review.</citation>
    <PMID>28537982</PMID>
  </reference>
  <reference>
    <citation>Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419838383. doi: 10.1177/2058738419838383. Review.</citation>
    <PMID>30900486</PMID>
  </reference>
  <reference>
    <citation>Lee-Kubli CA, Calcutt NA. Painful neuropathy: Mechanisms. Handb Clin Neurol. 2014;126:533-57. doi: 10.1016/B978-0-444-53480-4.00034-5. Review.</citation>
    <PMID>25410243</PMID>
  </reference>
  <reference>
    <citation>Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Can Fam Physician. 2015 Aug;61(8):e372-81. Review.</citation>
    <PMID>26505059</PMID>
  </reference>
  <reference>
    <citation>Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O'Hearn S. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. 2017 Dec;6(Suppl 2):S215-S222. doi: 10.21037/apm.2017.08.05. Epub 2017 Aug 23. Review.</citation>
    <PMID>28866904</PMID>
  </reference>
  <reference>
    <citation>Ligresti A, De Petrocellis L, Di Marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev. 2016 Oct;96(4):1593-659. doi: 10.1152/physrev.00002.2016. Review.</citation>
    <PMID>27630175</PMID>
  </reference>
  <reference>
    <citation>Sun J, Zhou YQ, Chen SP, Wang XM, Xu BY, Li DY, Tian YK, Ye DW. The endocannabinoid system: Novel targets for treating cancer induced bone pain. Biomed Pharmacother. 2019 Dec;120:109504. doi: 10.1016/j.biopha.2019.109504. Epub 2019 Oct 15. Review.</citation>
    <PMID>31627091</PMID>
  </reference>
  <reference>
    <citation>Mao Y, Huang Y, Zhang Y, Wang C, Wu H, Tian X, Liu Y, Hou B, Liang Y, Rong H, Gu X, Ma Z. Cannabinoid receptor 2-selective agonist JWH015 attenuates bone cancer pain through the amelioration of impaired autophagy flux induced by inflammatory mediators in the spinal cord. Mol Med Rep. 2019 Dec;20(6):5100-5110. doi: 10.3892/mmr.2019.10772. Epub 2019 Oct 25.</citation>
    <PMID>31661120</PMID>
  </reference>
  <reference>
    <citation>Boland EG, Bennett MI, Allgar V, Boland JW. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Support Palliat Care. 2020 Mar;10(1):14-24. doi: 10.1136/bmjspcare-2019-002032. Epub 2020 Jan 20.</citation>
    <PMID>31959586</PMID>
  </reference>
  <reference>
    <citation>Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig. 2014 Jul;34(7):501-11. doi: 10.1007/s40261-014-0204-3.</citation>
    <PMID>24906437</PMID>
  </reference>
  <reference>
    <citation>Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006 Oct;22(10):1911-20.</citation>
    <PMID>17022849</PMID>
  </reference>
  <reference>
    <citation>Freynhagen R, Baron R, Tölle T, Stemmler E, Gockel U, Stevens M, Maier C. Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr Med Res Opin. 2006 Mar;22(3):529-37.</citation>
    <PMID>16574036</PMID>
  </reference>
  <reference>
    <citation>Lee SH, Min YS, Park HY, Jung TD. Health-related quality of life in breast cancer patients with lymphedema who survived more than one year after surgery. J Breast Cancer. 2012 Dec;15(4):449-53. doi: 10.4048/jbc.2012.15.4.449. Epub 2012 Dec 31.</citation>
    <PMID>23346175</PMID>
  </reference>
  <reference>
    <citation>Rehberg B, Mathivon S, Combescure C, Mercier Y, Savoldelli GL. Prediction of Acute Postoperative Pain Following Breast Cancer Surgery Using the Pain Sensitivity Questionnaire: A Cohort Study. Clin J Pain. 2017 Jan;33(1):57-66.</citation>
    <PMID>27922844</PMID>
  </reference>
  <reference>
    <citation>Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308.</citation>
    <PMID>3687892</PMID>
  </reference>
  <reference>
    <citation>Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672-7. doi: 10.1016/j.ijsu.2011.09.004. Epub 2011 Oct 13.</citation>
    <PMID>22019563</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <reference>
    <citation>Pain: clinical manual for nursing practice Pain: clinical manual for nursing practice Margo McCaffery Alexander Beebe Mosby Yearbook UK £17.25 0 7234 1992 2. Nurs Stand. 1994 Dec 7;9(11):55. doi: 10.7748/ns.9.11.55.s69.</citation>
    <PMID>27527475</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabis based medicine</keyword>
  <keyword>d9-tetrahydrocannabinol</keyword>
  <keyword>Cannabidiol</keyword>
  <keyword>Cancer Pain</keyword>
  <keyword>Cancer Bone Pain</keyword>
  <keyword>Treatment</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>Nanoparticle</keyword>
  <keyword>Tetrahydrocannabinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

